Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 126 points (-0.7%) at 17,985 as of Wednesday, April 29, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 863 issues advancing vs. 2,117 declining with 156 unchanged.

The Drugs industry currently sits down 1.3% versus the S&P 500, which is down 0.8%. A company within the industry that increased today was

Valeant Pharmaceuticals International

(

VRX

), up 1.5%. On the negative front, top decliners within the industry include

AstraZeneca

(

AZN

), down 1.8%,

Novo Nordisk A/S

(

NVO

), down 1.8%,

Vertex Pharmaceuticals

(

VRTX

), down 1.8%,

Amgen

(

AMGN

), down 1.7% and

Pfizer

(

PFE

), down 1.4%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Teva Pharmaceutical Industries

(

TEVA

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Teva Pharmaceutical Industries is up $0.35 (0.6%) to $61.65 on light volume. Thus far, 1.8 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 5.8 million shares. The stock has ranged in price between $60.90-$61.96 after having opened the day at $60.90 as compared to the previous trading day's close of $61.30.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. Teva Pharmaceutical Industries has a market cap of $52.5 billion and is part of the health care sector. Shares are up 6.6% year-to-date as of the close of trading on Tuesday. Currently there are 14 analysts who rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Teva Pharmaceutical Industries

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, reasonable valuation levels and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Teva Pharmaceutical Industries Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Mylan

(

MYL

) is up $0.99 (1.4%) to $73.70 on average volume. Thus far, 5.4 million shares of Mylan exchanged hands as compared to its average daily volume of 8.4 million shares. The stock has ranged in price between $72.07-$74.38 after having opened the day at $72.48 as compared to the previous trading day's close of $72.71.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Mylan N.V., through its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. Mylan has a market cap of $27.1 billion and is part of the health care sector. Shares are up 29.0% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts who rate Mylan a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Mylan

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, solid stock price performance, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Mylan Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Biogen

(

BIIB

) is up $4.46 (1.2%) to $379.14 on heavy volume. Thus far, 1.8 million shares of Biogen exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $376.00-$385.16 after having opened the day at $377.97 as compared to the previous trading day's close of $374.68.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. Biogen has a market cap of $91.6 billion and is part of the health care sector. Shares are up 10.4% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts who rate Biogen a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Biogen

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Biogen Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null